Phospholipid‐Metabolizing Enzymes in Alzheimer's Disease: Increased Lysophospholipid Acyltransferase Activity and Decreased Phospholipase A2 Activity

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Neurochemistry

• Publication date

  1998-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1471-4159.1998.70020786.xPMID 9453575
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease

  2005cited by this paper
• Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA-1) mutation define a unique phenotype

  2004cited by this paper
• Phospholipid biosynthetic enzymes in human brain

  1997cited by this paper
• Phospholipase A2 Activity Is Selectively Decreased in the Striatum of Chronic Cocaine Users

  1996cited by this paper
• Activation of phospholipase A2 by amyloid beta-peptides in vitro.

  1996cited by this paper
• The Role of Arachidonic Acid in the Secretion of the Amyloid Precursor Protein (APP) a

  1996cited by this paper
• Phospholipid metabolism in Alzheimer's disease and in a human cholinergic cell.

  1996cited by this paper
• Brain S‐Adenosylmethionine Levels Are Severely Decreased in Alzheimer's Disease

  1996cited by this paper
• Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain.

  1996cited by this paper
• Therapeutic Effects of CDP‐Choline in Alzheimer's Disease‐Cognition, Brain Mapping, Cerebrovascular Hemodynamics, and Immune Factors a

  1996cited by this paper
• Lipid peroxidation inhibits acyl-CoA:-1-acyl-sn-glycero-3-phosphocholine O-acyltransferase but not CTP: phosphocholine cytidylyltransferase activity in rat brain membranes.

  1995cited by this paper
• Phospholipid abnormalities in early Alzheimer's disease. In vivo phosphorus 31 magnetic resonance spectroscopy.

  1995cited by this paper
• Multiple forms of the enzyme glycerophosphodiesterase are present in human brain

  1995cited by this paper
• Breakdown of membrane phospholipids in Alzheimer disease. Involvement of excitatory amino acid receptors.

  1995cited by this paper
• Evidence that 5′‐Cytidinediphosphocholine Can Affect Brain Phospholipid Composition by Increasing Choline and Cytidine Plasma Levels

  1995cited by this paper
• Osmotic regulation of synthesis of glycerophosphocholine from phosphatidylcholine in MDCK cells.

  1995cited by this paper
• Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia.

  1995cited by this paper
• Neural membrane phospholipids in alzheimer disease

  1995cited by this paper
• Characterization of a Novel Phospholipase A2 Activity in Human Brain

  1995cited by this paper
• Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain.

  1995cited by this paper
• Susceptibility of rat retina acyl‐CoA: 1‐acyl‐sn‐glycero‐3‐phosphocholine O‐acyltransferase and CTP:phosphocholine cytidylyltransferase activity to lipid peroxidation and hydroperoxide treatment

  1994cited by this paper
• Characterization of Lysophospholipid Metabolizing Enzymes in Human Brain

  1994cited by this paper
• 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease.

  1993cited by this paper
• A radical hypothesis for neurodegeneration.

  1993cited by this paper
• Conformational changes in oxidized phospholipids and their preferential hydrolysis by phospholipase A2: a monolayer study.

  1993cited by this paper
• Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1

  1993cited by this paper
• Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease.

  1993cited by this paper
• Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's demented controls

  1993cited by this paper
• New insights on mammalian phospholipase A2(s); comparison of arachidonoyl‐selective and ‐nonselective enzymes

  1993cited by this paper
• Hydrolysis of Glycerophosphocholine Hydroperoxide by Phospholipase A2

  1993cited by this paper
• Cholinephosphotransferase from mammalian sources.

  1992cited by this paper
• Evidence for a membrane defect in Alzheimer disease brain.

  1992cited by this paper
• Identification and Purification of Calcium‐Independent Phospholipase A2 from Bovine Brain Cytosol

  1992cited by this paper
• Characterization of phospholipase A2 (PLA2) activity in gerbil brain: enhanced activities of cytosolic, mitochondrial, and microsomal forms after ischemia and reperfusion

  1991cited by this paper
• Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients.

  1990cited by this paper
• Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras oncogene.

  1990cited by this paper
• Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease.

  1989cited by this paper
• Lewy Bodies in Alzheimer Disease‐One or Two Diseases?

  1989cited by this paper
• Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease.

  1988cited by this paper
• Reduced Phosphoinositide Concentrations in Anterior Temporal Cortex of Alzheimer‐Diseased Brains

  1987cited by this paper
• Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease.

  1987cited by this paper
• Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases.

  1987cited by this paper
• Reduced phospholipase D activity in brain tissue samples from Alzheimer's disease patients

  1986cited by this paper

• Spatially resolved transcriptome–metabolome integration reveals region-specific glial lipid dysregulation associated with Alzheimer’s pathology

  2026cites this paper
• Trajectory of plasma lipidome associated with the risk of late-onset Alzheimer's disease: a longitudinal cohort study

  2025cites this paper
• Exploring the Mechanism of Kai-Xin-San to Improve Cognitive Deficits in AD Rats Induced by D-Gal and Aβ25-35 Based on Multi-Omics and Network Analysis.

  2025cites this paper
• Lysophosphatidylcholines are associated with amyloidosis in early stages of Alzheimer’s disease

  2025cites this paper
• Differential impact of eicosapentaenoic acid and docosahexaenoic acid in an animal model of Alzheimer’s disease

  2024cites this paper
• Exploring the complexities of epigenetics in multiple sclerosis: A study involving meta-analysis of DNA methylation profiles, epigenetic drift, and rare epivariations

  2024cites this paper
• Lysophosphatidylcholines are associated with P-tau181 levels in early stages of Alzheimer’s Disease

  2024cites this paper
• Spatially and temporally probing distinctive glycerophospholipid alterations in Alzheimer’s disease mouse brain via high-resolution ion mobility-enabled sn-position resolved lipidomics

  2024cites this paper
• Lipid mediators in post-mortem brain samples from patients with Alzheimer's disease: A systematic review

  2024cites this paper
• iPLA2β loss leads to age-related cognitive decline and neuroinflammation by disrupting neuronal mitophagy

  2024cites this paper
• Modulation of Cytosolic Phospholipase A2 as a Potential Therapeutic Strategy for Alzheimer’s Disease

  2023cites this paper
• Lysophosphatidylcholines are associated with P-tau181 levels in early stages of Alzheimer’s Disease

  2023cites this paper
• Integrated brain and plasma dual-channel metabolomics to explore the treatment effects of Alpinia oxyphyllaFructus on Alzheimer’s disease

  2023cites this paper
• Trajectory of plasma lipidomes associated with the risk of late-onset Alzheimer's disease pathogenesis: a longitudinal study in the ADNI cohort

  2023cites this paper
• Molecular insights into sex-specific metabolic alterations in Alzheimer’s mouse brain using multi-omics approach

  2023cites this paper
• Systematic review of 31P-magnetic resonance spectroscopy studies of brain high energy phosphates and membrane phospholipids in aging and Alzheimer's disease

  2023cites this paper
• Mechanotransduction: Exploring New Therapeutic Avenues in Central Nervous System Pathology

  2022cites this paper
• Lipid Dys-Homeostasis Contributes to APOE4-Associated AD Pathology

  2022cites this paper
• CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status

  2021cites this paper
• Lipids: biomarkers of healthy aging

  2021cites this paper
• Conjugated Linoleic Acid and Brain Metabolism: A Possible Anti-Neuroinflammatory Role Mediated by PPARα Activation

  2021cites this paper
• Integrating metabolomics and network pharmacology to explore the protective effect of gross saponins of Tribulus terrestris L. fruit against ischemic stroke in rat.

  2020cites this paper
• Perspective: The Potential Role of Circulating Lysophosphatidylcholine in Neuroprotection against Alzheimer Disease.

  2020cites this paper
• Xanthoceraside Could Ameliorate Alzheimer’s Disease Symptoms of Rats by Affecting the Gut Microbiota Composition and Modulating the Endogenous Metabolite Levels

  2019cites this paper
• Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4-/-: A double-blind, randomized, placebo-controlled crossover trial.

  2019cites this paper
• Neurobiology and therapeutic applications of neurotoxins targeting transmitter release.

  2019cites this paper
• Macromolecular crowding and membrane binding proteins: The case of phospholipase A1.

  2019cites this paper
• Distinct disruptions in Land's cycle remodeling of glycerophosphocholines in murine cortex mark symptomatic onset and progression in two Alzheimer's disease mouse models

  2018cites this paper
• Altered brain high-energy phosphate metabolism in mild Alzheimer's disease: A 3-dimensional 31P MR spectroscopic imaging study

  2018cites this paper
• Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry.

  2018cites this paper
• Mechanisms of the active components from Korean pine nut preventing and treating d-galactose-induced aging rats.

  2018cites this paper
• Targeted biochemical profiling of brain from Huntington's disease patients reveals novel metabolic pathways of interest.

  2018cites this paper
• Metabolic status of CSF distinguishes rats with tauopathy from controls

  2017cites this paper
• Genetic research advance on neurodegeneration with brain iron accumulation

  2017cites this paper
• Effects of breviscapine on amyloid beta 1-42 induced Alzheimer's disease mice: A HPLC-QTOF-MS based plasma metabonomics study.

  2017cites this paper
• The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer’s disease: results from a randomized controlled trial

  2017cites this paper
• Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer’s disease

  2016cites this paper
• The Effects of Glycerophospholipids and Fatty Acids on APP Processing: Implications for Alzheimer’s Disease

  2016cites this paper
• Alteration of mitochondrial phospholipid due to the PLA2 activation in rat brains under cadmium toxicity.

  2016cites this paper
• The Role of the Glycerophosphocholine Remodelling in Alzheimer’s Disease

  2016cites this paper
• Serum Level and Genetic Polymorphism of Secretary Phospholipase A2-IIA in Alzheimer’s Disease. Med Chem (Los Angeles) 6:670-673.

  2016cites this paper
• Analytical approaches to the diagnosis and treatment of aging and aging-related disease: redox status and proteomics

  2015cites this paper
• Reduced activities of phospholipases A2 in platelets of drug-naïve bipolar disorder patients.

  2015cites this paper
• Long-Term Lithium Treatment Increases cPLA2 and iPLA2 Activity in Cultured Cortical and Hippocampal Neurons

  2015cites this paper
• Review: Insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories

  2015cites this paper
• Chronic inhibition of brain phospholipase A2 in adult rats impairs the survival of newborn mature neurons in the hippocampus

  2015cites this paper
• Conjugated linoleic acid-enriched butter improved memory and up-regulated phospholipase A2 encoding-genes in rat brain tissue

  2015cites this paper
• Protective effects of ginsenosides Rg1 and Rb1 on an Alzheimer's disease mouse model: a metabolomics study.

  2015cites this paper
• Fish oil supplementation increases event-related posterior cingulate activation in older adults with subjective memory impairment

  2015cites this paper
• Metabolomics-based promising candidate biomarkers and pathways in Alzheimer's disease.

  2015cites this paper
• The Impact of Docosahexaenoic Acid on Alzheimer's Disease: Is There a Role of the Blood-Brain Barrier?

  2015cites this paper
• Mass Spectrometry-based Lipidomics and Its Application to Biomedical Research

  2014cites this paper
• Cellular Membrane Fluidity in Amyloid Precursor Protein Processing

  2014cites this paper
• Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer's disease.

  2014cites this paper
• Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease.

  2014cites this paper
• Lysophosphatidylcholine and Amide as Metabolites for Detecting Alzheimer Disease Using Ultrahigh-Performance Liquid Chromatography–Quadrupole Time-of-Flight Mass Spectrometry–Based Metabonomics

  2014cites this paper
• Using direct infusion mass spectrometry for serum metabolomics in Alzheimer’s disease

  2014cites this paper
• Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's Disease

  2013cites this paper
• Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease[S]

  2013cites this paper
• Platelet biomarkers in Alzheimer's disease.

  2012cites this paper
• Alzheimer disease and platelets: how’s that relevant

  2012cites this paper
• Lipidomics of Alzheimer's disease: current status

  2012cites this paper
• A cellular lipidomic study on the Aβ-induced neurotoxicity and neuroprotective effects of EGCG by using UPLC/MS-based glycerolipids profiling and multivariate analysis.

  2012cites this paper
• DBGSA: a novel method of distance-based gene set analysis

  2012cites this paper
• Inhibition of phospholipase A₂ in rat brain modifies different membrane fluidity parameters in opposite ways.

  2011cites this paper
• A Novel Multiplex Cell Viability Assay for High-Throughput RNAi Screening

  2011cites this paper
• Impacts of Membrane Biophysics in Alzheimer's Disease: From Amyloid Precursor Protein Processing to Aβ Peptide-Induced Membrane Changes

  2011cites this paper
• Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein

  2011cites this paper
• From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry.

  2011cites this paper
• [Dysregulation of phospholipid metabolism of neuronal membranes in the nervous system pathology].

  2010cites this paper
• Enriquecimento ambiental como estratégia para promover a neurogênese na doença de Alzheimer: possível participação da fosfolipase A2

  2010cites this paper
• Environmental enrichment as strategy to promote neurogenesis in Alzheimer disease : possible participation of phospholipase

  2010cites this paper
• Membrane Biophysics and Mechanics in Alzheimer's Disease

  2010cites this paper
• Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry.

  2010cites this paper
• Differential roles of phospholipases A2 in neuronal death and neurogenesis: implications for Alzheimer disease.

  2010influential citation
• Deficiency of ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) leads to vulnerability to lipid peroxidation.

  2010cites this paper
• Nitric oxide: target for therapeutic strategies in Alzheimer's disease.

  2010cites this paper
• 13 Metabolism and Functions of Platelet-Activating Factor (PAF) in the Nervous Tissue

  2009cites this paper
• Amyloid-β42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism

  2009cites this paper
• Lipids in Alzheimer’s Disease Brain

  2009cites this paper
• Lysophospholipid acyltransferases: novel potential regulators of the inflammatory response and target for new drug discovery.

  2008cites this paper
• A possible role for sPLA2 in oligodendrocyte death and spinal cord injury.

  2008cites this paper
• Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.

  2008cites this paper
• Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease

  2008cites this paper
• Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia

  2008cites this paper
• Conditioning training and retrieval increase phospholipase A2 activity in the cerebral cortex of rats

  2008cites this paper
• Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme

  2008cites this paper
• Calcium‐independent phospholipase A2 influences AMPA‐mediated toxicity of hippocampal slices by regulating the GluR1 subunit in synaptic membranes

  2007cites this paper
• Platelet phospholipase A2 activity in patients with Alzheimer’s disease, vascular dementia and ischemic stroke

  2007cites this paper
• Amyloid beta enhances cytosolic phospholipase A2 level and arachidonic acid release via nitric oxide in APP-transfected PC12 cells.

  2007cites this paper
• Alzheimer Disease—No Target for Statin Treatment. A Mini Review

  2007cites this paper
• Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.

  2007cites this paper
• Requirement of hippocampal phospholipase A2 activity for long-term memory retrieval in rats

  2007cites this paper
• The role of phospholipase A2 in neuronal homeostasis and memory formation: implications for the pathogenesis of Alzheimer’s disease

  2007cites this paper
• Amyloid β ( Aβ ) accumulation , mitochondrial dysfunction and oxidative stress are early steps in the pathogenesis of Alzheimer ’ s disease ( AD )

  2007cites this paper
• [Phosphodiesterases that extracellularly produces a lysolipid mediator].

  2006cites this paper
• Nitric oxide alters arachidonic acid turnover in brain cortex synaptoneurosomes.

  2006cites this paper
• Alois Alzheimer revisited: differences in origin of the disease carrying his name

  2006cites this paper
• Inhibition of phospholipase A2 activity reduces membrane fluidity in rat hippocampus

  2005cites this paper
• AMPA receptor phosphorylation is selectively regulated by constitutive phospholipase A2 and 5‐lipoxygenase activities

  2005cites this paper